2 results
Approved WMOCompleted
Primary objective:To demonstrate that tralokinumab in combination with TCS is superior to placebo in combination with TCS in treating moderate-to-severe AD.Secondary objectives:To evaluate the efficacy of tralokinumab in combination with TCS on…
Approved WMOCompleted
* Primary Objective:To assess the effect of MEDI0382 on hepatic glycogen levels versus placebo after 28 days (Part A) and 35 days (Part B) of treatment* Secundary Objective: - To assess the effect of MEDI0382 on hepatic glycogen levels versus…